Nyxoah ( (NYXH) ) has shared an announcement.
On April 16, 2025, Nyxoah SA announced a conditional issuance of up to 5 million ordinary shares as part of its existing at-the-market equity offering programs. This move increases the total number of shares available for sale and issuance to 5,662,694, including shares from a previous issuance in December 2022. The shares will be sold at prevailing market prices on the Nasdaq Global Market, potentially impacting the company’s capital structure and market presence.
More about Nyxoah
Nyxoah SA operates in the medical technology industry, focusing on developing innovative solutions for the treatment of sleep apnea. The company is known for its minimally invasive neurostimulation therapy designed to treat Obstructive Sleep Apnea (OSA). Nyxoah is listed on Euronext Brussels and Nasdaq under the ticker NYXH.
YTD Price Performance: -33.85%
Average Trading Volume: 117,447
Technical Sentiment Signal: Buy
Current Market Cap: $212.6M
For detailed information about NYXH stock, go to TipRanks’ Stock Analysis page.